APA: Most Bipolar Patients Start on Off-Label Antidepressants
(May 24, 2007) -- SAN DIEGO -- Antidepressants are widely used to treat
the depression in
bipolar disorder, despite their lack of approval for the indication and
limited evidence of efficacy and safety, investigators reported here.
| Action Points
--Explain to patients who ask that
drug therapy for depression associated with bipolar disorder
may include mood stabilizers and/or antimanic agents.
--This study was published as an
abstract and presented orally at a conference. These data
and conclusions should be considered to be preliminary as
they have not yet been reviewed and published in a
peer-reviewed publication. |
|
A review of nationwide prescribing patterns of psychotropic drugs for
patients with diagnosed bipolar disorder revealed that more than half
received
antidepressants as initial monotherapy, with anticonvulsant drugs coming
in a distant second, reported Ross J. Baldessarini, M.D., of Harvard, and
colleagues.
"Utilization rates for antidepressants were very high despite a lack of
compelling evidence of their efficacy or safety in bipolar depression, and
polytherapy came to dominate treatment by one year," the investigators wrote
in a poster presentation at the meeting of the American Psychiatric
Association here.
The FDA has approved several antimanic and
mood stabilizing agents for the treatment of depression associated with
bipolar disorder. Antidepressants, although not approved for this
indication, are increasingly being used off-label as monotherapy and in
combination, the authors noted.
To get a snapshot of how specific drugs and combinations are being used
to treat bipolar disorder, the investigators used a HIPAA-compliant,
national health-plan claims database for the years 2000 through 2004 to
identify patients with an International Classification of Diseases, 9th
revision (ICD-9) diagnosis of bipolar disorder.
To be included in the study, all patients had to have continuous
benefits, have at least one prescription filled for bipolar disease therapy
in the study period, and to have been untreated in the six months before the
index prescription was filled.
They identified a total of 7,567 patients with bipolar disorder, 57% men,
43% women, with a mean age of 35.5 ± 12.4 years. In all, 55.2% of patients
had type I bipolar disorder, 14.5% had type II, and 30.3% had a disorder not
otherwise specified.
The large majority of the patients (74.9%) had one initial prescription,
while the remaining 36.1% had prescriptions for two or more mood-altering
drugs.
The initial monotherapies, in rank from first to last, were:
- Antidepressants: 56.1%
- Anticonvulsants: 13.9%
- Antipsychotics: 10.6%
- Lithium: 5.7%
Among the patients receiving anticonvulsants,
valproate (Depakote, Depakene) was prescribed for 10.2%,
lamotrigine (Lamictal) for 2.9%, and
carbamazepine (Carbetrol, Tegretol) for 0.8%.
Initial and overlapping combinations included: antidepressants in 9.9%,
antipsychotics in 8.9%, anticonvulsants in 7.3%, lithium in 2.3%. The rank
order for combinations was the same at one year, with 36.1% of patients
still receiving monotherapy, 25.7% receiving two or more psychotropics, and
38.2% getting nothing.
Psychotropic prescriptions per patient averaged 1.29 at baseline, and
1.52 at one year. Among the 5,666 patients who initially filled just one
prescription, 68.6% were for antidepressants, 14.6% were for
anticonvulsants, 10.8% were for antipsychotics, and 6.0% were for lithium.
The proportions were roughly the same for 2,732 patients who remained on
monotherapy at one year.
Among 1,945 patients who were on combination therapy at one year, 83.4%
were taking antidepressants, 58.2% antipsychotics, 56.3% anticonvulsants,
and 23.6% were receiving lithium.
At one year, the largest proportion of patients, 39% were receiving no
drug treatment for bipolar disorder.
"Combination therapy and no medication came to dominate treatment by one
year," the authors wrote. "Prevalent non-treatment at 12 months encourages
development of better-tolerated mood-stabilizing treatments."
| The study was funded by Novartis, the Bruce J. Anderson
Foundation, and the McLean Private Donors Research Fund. Dr.
Baldessarini is a consultant to Novartis, and his co-authors are
employees of either i3-Innovus, a market research firm, or Novartis.
|
Primary
source: American Psychiatric Association 2007 Annual Meeting
Source reference: Baldessarini, RJ et al. "Use of Psychotropics by
American Bipolar Disorder Patients (2001-2004)." Abstract NR373, presented
May 22.
By: Neil Osterweil, Senior associate Editor, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine,
University of California, San Francisco
Source: MedPage Today
Last updated: 05/07
Related Information:
back to
top ~ bipolar news index~
send page to a
friend |